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Abstract: Immune thrombocytopenic purpura (ITP) is an
autoimmune disease that affects thousands of Americans
each year. The resulting thrombocytopenia, which develops
from destruction of platelets (PLT) by anti-PLT autoantibod-
ies (APAb), is often associated with hemorrhagic complica-
tions. Existing therapies are not effective and are associated
with significant morbidity. Recently, a new treatment mo-
dality using plasmapheresis with a Protein-A column has
shown some clinical promise. Yet, although this method
would remove the pathogenic APAb, it would also deplete
protective antibodies, thereby weakening the body’s self-
defense system. Because about 80% of patients with ITP
develop APAb against the GPIIb/IIIa antigens on PLT, a
novel approach of attaching a GPIIb/IIIa-linked bioreactor
with an extracorporeal circuit is suggested herein to achieve
highly effective/specific APAb removal and overcome
shortcomings of plasmapheresis in treating ITP. A hollow
fiber-based bioreactor device was fabricated, and GPIIb/IIIa
antigens were immobilized onto the inner lumens of the
hollow fibers by using the epichlorohydrin activation
method. An optimized bioreactor containing a loading of
1.63 mg GPIIb/IIIa/g fibers and adsorption capacity of 1.9
mg 7E3/g fibers was developed. Preliminary proof-of-con-
cept investigation using a 7E3-induced thrombocytopenic
rat model (which mimicked clinical ITP) was carried out. A
complete (100%) return of PLT counts to their initial levels
was observed in rats within 6 h after the GPIIb/IIIa biore-
actor treatment. In addition, a rapid restoration of WBC
counts in the treated rats was also found. These preliminary
findings shed light of promise of using the GPIIb/IIIa bio-
reactor approach in achieving highly improved ITP therapy.
© 2005 Wiley Periodicals, Inc. J Biomed Mater Res 75A:
648–655, 2005
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INTRODUCTION
Immune thrombocytopenic purpura (ITP) is a com-
mon autoimmune disease with an estimated incidence
rate of 10–125 per million persons each year.1 Thrombo-
cytopenia in ITP develops as a result of an enhanced
destruction of platelets (PLT), which is precipitated by
the interaction of autoantibodies and PLT antigens.2 The
resulting thrombocytopenia is often dramatic and asso-
ciated with a variety of hemorrhagic sequelae, including
epistaxis, oral mucosal bleeding, petechiae, hematuria,
gastrointestinal bleeding, and intracranial hemorrhage.
Currently accepted treatments for ITP include phar-
macological immunosuppression, splenectomy, and
intravenous immunoglobulin (IVIG) therapy, which
includes administration of a heterogeneous pool of
human IgG, IgM, and IgA. Unfortunately, pharmaco-
logical immunosuppression places patients at risk for
the development of opportunistic infections and, for
most patients, is not able to maintain platelet counts
30  109/L, the value typically accepted as sufficient
to provide prophylaxis against severe hemorrhage.1
On the other hand, splenectomy is associated with
considerable morbidity and incomplete efficacy, par-
ticularly in patients with chronic ITP.3 Subsequently,
Imbach and coworkers reported that large doses of
IVIG increases platelet counts in patients with ITP.4
The efficacy of IVIG was further confirmed by a num-
ber of additional studies.5–9 However, IVIG effects are
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typically short-lived, and the exceptionally high cost
of this therapy prohibits the possibility for long-term
applications to ITP patients with chronic disease.10,11
In addition, this IVIG treatment is beset by certain
serious complications.12–18 Several new therapeutic
modalities are currently under investigation for the
treatment of ITP, including 1) application of Protein-A
immunoadsorption by using a PROSORBA column19;
2) administration of recombinant thrombopoietin20,21;
and 3) administration of immunoglobulin with a high
titer of Anti-Rho (D) antibodies.22,23 Nevertheless,
these experimental therapies have all encountered sig-
nificant shortcomings and risks. For instance, given
the evidence that antiplatelet antibodies (APAb) are
responsible for the increased rate of PLT destruction
observed in ITP, immunoadsorptive plasmapheresis
has been developed to accelerate the removal of
pathogen antibodies. Indeed, this method using the
PROSORBA column has been approved by the Food
and Drug Administration (FDA) for clinical use in
treatment of ITP.19,24,25 The PROSORBA column is
made of silica gel containing immobilized Protein-A, a
bacterial protein that binds the Fc region of immuno-
gammaglobulin with high affinity.26 Although this
PROSRBA column removes pathological antibodies
and immune complexes from the patient, it also de-
pletes protective antibodies, thereby weakening the
body’s self-defense system and increasing patient sus-
ceptibility to opportunistic infections. In addition, Pro-
tein-A therapy has also been associated with a variety
of thrombotic disorders including stroke.27,28
In this work, we proposed a novel bioreactor ap-
proach, designed to specifically remove APAb from
blood, to overcome the limitations of extracorporeal
APAb removal by the nonspecific Protein-A column.
Because 80% of patients with ITP develop antibodies
directed against GPIIb/IIIa of PLT,29 GPIIb/IIIa was
selected as the specific antigen for the development of
this bioreactor.
The bioreactor developed herein consists of a hol-
low fiber-based device consisting of the GPIIb/IIIa
antigens that are covalently coupled to the inner lu-
mens of the hollow fibers by using the well-estab-
lished epichlorohydrin activation method.30,31 Several
design parameters were characterized to optimize the
antigen-loading and adsorption capacity of the biore-
actor. Preliminary in vivo studies involving rats were
also carried out to provide proof-of-concept of this
novel bioreactor-based approach to treat ITP.
MATERIALS
Cellulose hollow fibers were obtained by disassembling a
Baxter Model CF 25 hemodialyzer (Baxter Healthcare Cor-
poration, Deerfield, IL, USA). Each hollow fiber, with an
internal diameter of 20 m and a wall thickness of 10 m, is
made of a Cuprophan membrane with a 10-kDa molecular
weight cutoff. Epichlorohydrin, ethanol amine, sodium hy-
droxide, and bromothymol blue were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Human GPIIb/
IIIa was purchased from Enzyme Research Laboratories
(South Bend, IN, USA). The monoclonal antiplatelet anti-
body, 7E3, was generously supplied by Dr. Joseph Balthasar
at The State University of New York at Buffalo, New York.
Buffers were prepared by using certified ACS reagents and
in distilled, deionized water (ddH2O).
METHODS
Fabrication of the bioreactor device
The hollow fibers were cut to a length of 10 cm, measured
to a dry weight of 1 g, and then bonded together with
silicone. After allowing the silicone to dry and harden at
room temperature, the tips of the fiber bundle were cut to
remove any silicone blockage of the fiber openings. The
bundle was then housed in a glass tube (inner diameter ca.
1.2 cm) that is fitted with a luer connector at each end. Figure
1 presents an illustration of the bioreactor device. The pre-
pared bioreactor possesses hemodynamic characteristics
that mimic clinically used hemodialyzers.
Activation of the hollow fiber-based bioreactor
The hollow fiber-based bioreactor fabricated above was
activated by circulating 10 mL of 0.8M sodium hydroxide,
containing 0.5 mL epichlorohydrin, for 2 h at 40°C. The
bioreactor was then washed repeatedly with a large volume
of ddH2O until no epichlorohydrin could be detected. To
determine the presence of epichlorohydrin, 2 mL of flow
through water was put into a glass tube followed by the
addition of 1 mL of 1.3M sodium thiosulfate solution and 1
drop of bromothymol blue solution (indicator). A blue color
indicated the presence of epichlorohydrin, whereas a yellow
color signified a complete removal of this activating agent.
Determination of epoxy groups on the activated
hollow fibers
Content of the epoxy groups on the epichlorohydrin-acti-
vated hollow fibers was determined by titration.32 Briefly,
Figure 1. Schematic illustration of the fabricated bioreactor
device.
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the hollow fiber bioreactor was first washed with ddH2O.
After removing the water, 1.3M sodium thiosulfate solution
was circulated through the bioreactor for a half hour at room
temperature. The epoxy content in the bioreactor was then
determined by titration of the rinsed thiosulfate solution with
0.01M hydrochloric acid by using bromothymol blue as the
indicator. The change of color from blue to yellow indicates the
titration end point where the moles of hydrochloric acid con-
sumed were equal to the moles of epoxy in the bioreactor.
Coupling of GPIIb/IIIa onto the activated hollow
fiber bioreactor
GPIIb/IIIa solution (0.5 mg/mL in 0.15M PBS buffer, pH
8.3) was circulated through the bioreactor for 12 h at 40°C.
The bioreactor was then washed with 0.15M PBS buffer (pH
7.4). Unreacted epoxy groups were blocked by reacting with
1M ethanol amine, in 0.1M borate buffer at pH 8.0, for
overnight at room temperature. The bioreactor was then
washed with ddH2O, PBS buffer (pH 7.4), NaCl (2M), and
then stored at 40°C. The amount of coupled GPIIb/IIIa was
determined by measuring the GPIIb/IIIa concentration in
solution before and after circulation, according to the
method of Bradford.33
Coupling of albumin onto activated hollow fiber
An albumin bioreactor was developed to assess the non-
specific binding of monoclonal antiplatelet antibody, 7E3.
Albumin was coupled onto epichlorohydrin-activated hol-
low fibers according to the same procedures described
above. The amount of immobilized albumin was determined
by measuring the initial and final albumin concentrations in
the coupling solution.33
Leakage of coupled GPIIb/IIIa
To determine the degree of leakage of GPIIb/IIIa from the
bioreactor, PBS buffer (10 mL, pH 7.4) was circulated
through the GPIIb/IIIa-coupled bioreactor at room temper-
ature over a period of 4 days. The PBS elution was carried
out, by using 100 L fresh PBS buffer, every 30 min for 3 h
and then everyday for 4 days. Leakage was determined by
measuring the GPIIb/IIIa concentration in the eluting solu-
tion by using the Bradford protein assay method.33 The
degree of leakage was expressed as the percentage of eluted
GPIIb/IIIa relative to the amount of immobilized GPIIb/
IIIa.
In vitro adsorption test of monoclonal antiplatelet
antibody (7E3)
The adsorption of 7E3 antibodies on the GPIIb/IIIa biore-
actor was examined in vitro. In brief, the bioreactor was
washed with PBS buffer (pH 7.4) at a flow rate of 5 mL/min.
The 7E3 antibody solution (0.25 mg/mL) was then pumped
through the bioreactor at the same flow rate for 20 min at
room temperature. The amount of 7E3 antibodies adsorbed
onto the bioreactor was determined by measuring 7E3 con-
centrations before and after the adsorption process accord-
ing to the method of Bradford.33 The adsorption of 7E3 onto
a sham bioreactor was used as the control to assess the
degree of nonspecific adsorption of 7E3 onto plain hollow
fibers.
Desorption of 7E3 and repeated uses of the
bioreactor
Desorption of 7E3 was studied by circulating a 0.1M
amino acetic acid solution through the 7E3-adsorbed GPIIb/
IIIa bioreactor at room temperature for 2 h. The final 7E3
concentrations in the eluant were determined.
To test the reusability of the GPIIb/IIIa bioreactor, the 7E3
adsorption-desorption procedure was repeated 8 times over
a period of 40 days with the same bioreactor. Furthermore,
repeated use of the GPIIb/IIIa bioreactor on the same day
was investigated. Leakage of GPIIb/IIIa from the bioreactor
after 7E3 desorption was also examined.
Preliminary in vivo, proof-of-concept of the
bioreactor approach in rats
Female Sprague-Dawley rats, 200–250 g, were used for in
vivo testing of the feasibility of the bioreactor approach. The
aortal artery and the jugular vein of the rat were cannulated,
and to the cannulas a hollow fiber bioreactor was attached to
form a simple extracorporeal bypass loop. A dose of 4
mg/kg of 7E3 was administered via the jugular vein cannula
of the rat to induce thrombocytopenia. Control animals were
dosed with an equal volume of sterile saline. Extracorporeal
circulation through the bioreactor was initiated 1 h after
administration of 7E3 (or saline), when platelet counts are
expected to be 15–25% of initial values (i.e., in 7E3-treated
animals). Heparin (250 mg/mL) was administered via the
jugular vein cannula to prevent coagulation in the bioreactor
and extracorporeal loop. Figure 2 provides a schematic of
the in vivo experimental setup.
Figure 2. In vivo experimental setup.
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Animals were tested in three groups: 1) a control group
consisting of rats receiving 7E3; 2) a second control group of
rats connected with an albumin-bioreactor and receiving
7E3; and 3) a treatment group of rats connected with the
GPIIb/IIIa bioreactor and receiving the 7E3 antiplatelet an-
tibody. Because this was a preliminary proof-of-concept in-
vestigation in animals, each group consisted of only three
rats.
The blood was circulated through the hollow fiber device
at a flow rate of 3 mL/min for 1 h. Platelet counts were
determined in PLT rich plasma by using a Z1-Dual Coulter
Counter fitted with a 70-mm aperture tube, just before dos-
ing and at 1, 3, 6, 12, and 24 h after dosing. Concentrations
of 7E3 were measured by using the ELISA assay.34
Animal studies were conducted at Dr. Balthasar’s labora-
tory at the State University of New York at Buffalo (SUNY-
Buffalo). SUNY-Buffalo is fully accredited by the AAALAC,
and the animal care and use program conforms to the stan-
dards in the “Guide for the Care and Use of Laboratory
Animals,” DHEW Pub. No. (NIH) 80-23, revised 1985.
RESULTS AND DISCUSSION
Activation of hydroxyl-containing polymers with
epichlorohydrin in alkaline medium has been used
widely for the preparation of adsorbents for bio-spe-
cific affinity chromatography.35 To optimize the func-
tionality of the GPIIb/IIIa bioreactor, the effects of
several parameters on the loading and adsorption ca-
pacity of the bioreactor were examined.
Optimization of GPIIbIIIa immobilization
Effects of epichlorohydrin concentration on hollow
fiber activation
Solutions (10 mL) containing various concentrations
of epichlorohydrin were circulated through the hol-
low fiber bioreactors at 40°C for 2 h. Figure 3 shows
the amount of epoxy groups on the bioreactor in-
creased with increasing epichlorohydrin concentra-
tions until a plateau was reached. Indeed, by using
1.0-g hollow fibers, as much as 30 M hydroxyl
groups could be activated when a 1.25% epichlorohy-
drin solution was used. The solution that contained
0.5% epichlorohydrin solution was found to yield suf-
ficient activation (i.e., 26 M epoxy per gram fiber)
and, therefore, was used in subsequent experiments.
Effect of temperature and duration of coupling on
GPIIb/IIIa loading
The GPIIb/IIIa coupling reaction was carried out
under varying conditions as listed in Table I. The
amount of GPIIb/IIIa coupled to the bioreactor de-
pended on both the coupling temperature and dura-
tion. Higher amounts of GPIIb/IIIa loading were ob-
served as the coupling temperature and/or the
coupling time are increased. A maximum of 1.624 mg
of GPIIb/IIIa per gram of fiber was obtained when the
coupling reaction was carried out at 90°C over 6 h.
When conducted at 70°C over 6 h, the coupling yield
was approximately 85% of the maximum obtained at
90°C. Although immobilized GPIIb/IIIa was found to
be relatively stable under extreme experimental con-
ditions, these exceedingly high temperatures (e.g.,
70°C), nevertheless, introduced a significant degree
of denaturation of the coupled GPIIb/IIIa (data not
shown). On the other hand, room temperature was
found to yield a low GPIIb/IIIa loading; 23% of the
maximum loading was attained even with coupling
times as long as 72 h. Therefore, the optimal condi-
tions for GPIIb/IIIa coupling were selected at 40°C for
12 h, simply because such conditions provided a yield
of 90% compared to the maximum value. In addition,
these conditions did not elicit any obvious impairment
with regard to the binding affinity of the coupled
GPIIb/IIIa toward 7E3.
Effect of coupling pH on GPIIb/IIIa loading
The optimum pH for GPIIb/IIIa coupling was ex-
amined by varying pH of the coupling buffers while
the coupling conditions were set at 40°C for 12 h.
Figure 4 shows that there was a strong dependence
between the amount of GPIIb/IIIa coupled and the pH
in the coupling buffer. On the basis of these results,
Figure 3. Effect of ephichlorohydrin concentration on the
introduction of epoxy groups to the hollow fiber surface.
Experımental details were provided in the Methods section.
All measurements were performed in triplicate. Error bars
represented standard deviation.
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the optimum pH for GPIIb/IIIa coupling was deter-
mined to be 8.3.
Effect of concentration of coupling buffer on GPIIb/
IIIa loading
To evaluate the effect of the buffer concentration on
coupling efficiency, PBS buffers (pH 8.3) of varying
concentrations were used while maintaining the cou-
pling reactions at 40°C for 12 h. Figure 5 shows that
the optimum buffer concentration was 0.15M PBS
buffer.
Effect of GPIIb/IIIa concentrations on loading
The effects of the GPIIb/IIIa concentrations in the
coupling solution on GPIIb/IIIa loading were studied
in the range of 0–1 mg/mL. Figure 6 shows that the
amount of coupled GPIIb/IIIa increased with increas-
ing GPIIb/IIIa concentration but reached a maximum
at 0.5 mg/mL. However, further increase in the
GPIIb/IIIa concentration resulted in a decrease in the
amount of coupled GPIIb/IIIa, a phenomenon that
was probably attributed to the high viscosity in the
coupling solution. Therefore, the optimum GPIIB/IIIa
concentration to be used in the coupling reaction was
determined to be 0.5 mg/mL.
In vitro characterization of the GPIIb/IIIa
bioreactor
Adsorption and desorption of 7E3 antibodies by the
GPIIb/IIIa bioreactor
To test the ability of the GPIIb/IIIa bioreactor in
removing 7E3 antibodies, solutions containing 0.25
mg/mL 7E3 were circulated through the bioreactors
prepared in Figure 6 with different GPIIb/IIIa load-
ings at 37°C for 20 min. The results also plotted in
TABLE I












25 12 0.125 7.7
72 0.366 22.5
40 3 0.825 50.8
6 1.150 70.8
12 1.465 90.2
70 6 1.380 85.0
90 6 1.624 100.0
Figure 4. Effect of pH on coupling of GPIIb/IIIa to the
bioreactor. Experımental details were provided in the Meth-
ods section. All measurements were performed in triplicate.
Error bars represented standard deviation.
Figure 5. Effect of buffer concentration on coupling of
GPIIb/IIIa. Experımental details were provided in the Meth-
ods section. All measurements were performed in triplicate.
Error bars represented standard deviation.
Figure 6. Effect of GPIIb/IIIa concentration on coupling of
GPIIb/IIIa. Experımental details were provided in the Meth-
ods section. All measurements were performed in triplicate.
Error bars represented standard deviation. (F) represents
the amount of coupled GPIIb/IIIa, whereas (■) represents
the amount of adsorbed 7E3.
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Figure 6 show that the adsorption capacity of the
bioreactor toward 7E3 increased with the increase of
the GPIIb/IIIa loading in these bioreactors. A maxi-
mum 7E3 adsorption capacity of 1.90 mg/g fiber was
observed for the bioreactor containing the maximum
loading of 1.46 mg GPIIb/IIIa/g fibers. In comparison,
the nonspecific 7E3 adsorption onto a sham bioreactor
was only 0.17 mg/g fibers.
Desorption of 7E3 from the GPIIb/IIIa bioreactor
was also examined. Up to 93% of the adsorbed 7E3
was recovered from the bioreactor after four cycles of
washings using 0.1M aminoacetic acid as the eluting
agent. The elution of the bioreactor by aminoacetic
acid likely changed the charges or, in other words, the
isoelectric point of GPIIb/IIIa side groups, resulting in
the detachment of 7E3 from the bioreactor. It should
be noted that there was no detectable GPIIb/IIIa re-
lease from the bioreactor, indicating that GPIIb/IIIa
molecules were stably and covalently immobilized to
the epichlorohydrin-activated hollow fibers. With
these desorption results, it was concluded that amin-
oacetic acid was a suitable agent to regenerate an
already used GPIIb/IIIa bioreactor.
Stability and reusability of the GPIIb/IIIa bioreactor
To evaluate the stability and shelf-life of the biore-
actor, leakage of GPIIb/IIIa from the bioreactor was
examined by filling the interior of the bioreactor with
PBS buffer (pH 7.4) and then storing it at room tem-
perature for 4 days. At specific time intervals, 100 L
of the filling solution was withdrawn to determine the
degree of leakage of GPIIb/IIIa. Data showed that, on
average, 1% of the initially loaded GPIIb/IIIa was
leached off from the bioreactor after each day of stor-
age, and a total of 3% of the initially loaded GPIIb/IIIa
were lost during the entire span of 4 days of storage.
Hence, the GPIIb/IIIa bioreactor thus prepared ap-
pears to possess a reasonable shelf-life for its potential
clinical application.
To evaluate the reusability of the GPIIb/IIIa biore-
actor, the 7E3 adsorption/desorption cycle discussed
above was repeated six times over a period of 20 days
(i.e., one cycle every 4 days) with the same bioreactor.
Results showed that the capacity of the bioreactor
toward 7E3 adsorption was reduced by an approxi-
mate rate of 2% per cycle of reuse. At the 20-day mark,
87% of the initial 7E3 adsorption capacity of the bio-
reactor remained.
To further assess the reusability of the GPIIb/IIIa
bioreactor on a daily basis, the adsorption-desorption
cycle was repeated three times over a 1-day period
with the same bioreactor. Results showed that there
was no statistically significant reduction in the adsorp-
tion capacity of the GPIIb/IIIa bioreactor. By com-
pounding these findings together, it was concluded
that the reduction in adsorption capacity of the biore-
actor was probably less likely due to the experimental
conditions during its usage, but more to do with the
storage time.
Preliminary in vivo proof-of-concept studies in rats
Very preliminary proof-of-concept type of investiga-
tion was carried out on rats to show the feasibility of the
bioreactor approach in treating ITP. Thrombocytopenia
was induced in rats by administration, via the jugular
vein cannula of the animal, of a dose of 4 mg/kg of 7E3.
The ITP-induced rats were then distributed into three
subgroups (three rats per group): 1) control group in
which the rats were connected with a sham bioreactor; 2)
experimental group in which the rats were connected
with a GPIIb/IIIa bioreactor; and 3) another control
group in which the rats were connected with an albu-
min-linked bioreactor to determine the degree of non-
specific adsorption of 7E3 onto the hollow fiber-based
device. Extracorporeal circulation through the bioreactor
was initiated 1 h after administration of 7E3. Figure 7
presents a representative picture that illustrates the trend
of changes in platelet counts in animals in response to
the bioreactor treatment. As seen, 1 h after 7E3 injection,
PLT counts in all of the animals were reduced to 15–25%
of their initial values, a typical 7E3-induced thrombocy-
topenic response in rats as reported elsewhere.36 In both
control groups, the PLT counts continued to remain
exceedingly low over at least 12 h and then started to
slightly rebound gradually. These results suggested a
sustained PLT destruction due to the presence of the 7E3
antibodies. It appeared that there was very limited non-
specific adsorption of 7E3 on the hollow fiber-based
bioreactor, because the albumin-coated bioreactor
yielded similar PLT destruction as that of the sham bio-
Figure 7. Platelet count in 7E3-injected rats treated with
the albumin and GPIIb/IIIa bioreactors. (F) represents the
control group in which the rat was attached with a sham
bioreactor, (Œ) represents the experimental in which the rat
was attached with a GPIIb/IIIa bioreacotr, and (■) repre-
sents another control group in which the rat was attached
with an albumin-linked bioreactor.
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reactor. In sharp contrast, rats that received the GPIIb/
IIIa bioreactor treatment displayed a remarkably rapid
rebound in PLT counts, because the PLT count com-
pletely returned to the initial healthy level that was
measured before any bioreactor treatment (Fig. 7).
Measurements of the blood-free 7E3 concentrations
of the treated animals by using the ELISA assay
yielded comparable results. Five hours after the bio-
reactor treatment, 7E3 concentrations in the sham and
albumin bioreactor-treated groups were reduced by
20% and 25%, respectively. In contrast, the 7E3 con-
centration in the GPIIb/IIIa bioreactor-treated rats
was markedly reduced by 50%. At the 24-h mark after
the treatment, approximately 80% of the administered
7E3 was removed by the GPIIb/IIIa bioreactor. By
correlating these results with those seen in Figure 7 in
the change of PLT counts, it is obvious that specific
removal of the 7E3 antibodies would significantly re-
tard the destruction of PLT, thereby providing a useful
means to combat ITP.
It should be pointed out that, in practice, the use of an
extracorporeal GPIIb/IIIa bioreactor could never com-
pletely (i.e., 100%) deplete the 7E3 autoantibodies pro-
duced in ITP. This is because the extracorporeal circuit
only represents one of the many branches involved in
blood circulation in the body. Hence, when the bioreac-
tor-filtered blood returns to the patient, this specific 7E3-
free bloodstream will be mixed with blood from other
branches that contain 7E3. As a consequence, the con-
centration of 7E3 can only be reduced to a minimum
value regardless of the GPIIb/IIIa bioreactor efficiency
and number of blood circulation cycles. On the other
hand, based on the preliminary results shown in Figure
7, it may not be necessary to achieve a 100% antiplatelet
antibody removal.
To examine the hematological effects of the bioreactor
treatment, the red blood cell (RBC) count, white blood
cell (WBC) count, and total hemoglobin content in the
treated animals were analyzed. As expected, the RBC
count and total hemoglobin content remained virtually
unchanged over the entire course of experiments for all
of the three animal groups. It is of interest that the WBC
counts in both the control groups (i.e., animals treated
with a sham or an albumin bioreactor) decreased to
about 20% of their initial values 1 h after the treatment
and then returned to the initial values approximately 9 h
after the treatment. On the other hand, WBC counts in
the GPIIb/IIIa-treated rats were only reduced to 50% of
their initial values 1 h after the treatment and then re-
bounded rapidly to the initial values within a mere 5 h
after the GPIIb/IIIa treatment.
CONCLUSIONS
Given the evidence that antiplatelet antibodies
(APAb) are responsible for the increased rate of PLT
destruction observed in ITP, it is of no surprise that
recently increased attention has been given to ap-
proaches that will lead to an accelerated removal of
these pathogenic antibodies. Indeed, the immunoad-
sorptive plasmapheresis method by using the
PROSORBA column has been approved by the FDA
for clinical trials.24,25 Despite some clinical promise, a
recent ITP “practice guideline” prepared by a panel of
the American Society of Hematology listed Protein-A
therapy for refractory ITP patients (i.e., refractory to
prednisone and splenectomy) as a low preference
therapy compared with IVIG.1 This low preference
given to Protein-A plasmapheresis was apparently at-
tributed to the nonspecific nature of this therapy; all
IgG would be extracted from plasma, thereby increas-
ing the patient’s susceptibility to opportunistic infec-
tions. To this regard, the proposed approach possesses
the potential to overcome all these shortcomings asso-
ciated with the PROSORBA approach concomitantly.
First, the GPIIb/IIIa bioreactor will specifically re-
move APAb, and thus patients will not be immuno-
compromised through removal of nonpathogenic IgG.
Second, the new system does not use Protein-A or
silica, two components that have been known to cause
thrombosis after their leaching from the PROSORBA
column and into the patient’s blood stream. Third,
unlike the PROSORBA device that is established on
silica gels, the proposed system is built on cellulose
hollow fibers. A hollow fiber-based bioreactor offers
unmatched advantages over a particulate-based de-
vice because it is nonresistant to blood flow and does
not require separation of blood components during its
operation.
Overall, the preliminary findings presented in this
article were extremely promising, implicating that the
development of a highly improved new alternative in
treating ITP is reasonably plausible. Continued stud-
ies to further optimize the loading and adsorption
capacity of this GPIIb/IIIa bioreactor, as well as to
confirm the real-time feasibility of this approach via
extensive animal testing, are currently underway in
our laboratory.
The authors thank Feng Jin, Department of Pharmaceu-
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